Iovance Reports 50% Response Rate for Lifileucel in Sarcoma Study
Iovance reported a 50% confirmed objective response rate, with all responses ongoing, in advanced soft tissue sarcomas. The data were presented at the ESMO 2026 Congress.
Iovance reported a 50% confirmed objective response rate, with all responses ongoing, in advanced soft tissue sarcomas. The data were presented at the ESMO 2026 Congress.